• Explore /
  • Poster
  • / Circulating tumor cells (CTCs) in patients with metastatic castration resistant prostate cancer (mCRPC) treated with olaparib plus <sup>177</sup>lutetium-prostate specific membrane antigen-617 (<sup>177</sup>Lu-PSMA-617) in the LuPARP trial.

Circulating tumor cells (CTCs) in patients with metastatic castration resistant prostate cancer (mCRPC) treated with olaparib plus 177lutetium-prostate specific membrane antigen-617 (177Lu-PSMA-617) in the LuPARP trial.

Abstract Poster

Authors

null

Anis Hamid

Department of Medical Oncology, Peter MacCallum Cancer Centre and University of Melbourne, Melbourne, Australia

Anis Hamid , Santosh Gupta , Shivakumar Keerthikumar , Anupama Pasam , Megan Crumbaker , Anthony M. Joshua , Ernest Lam , Rick Wenstrup , Louise Emmett , David L. Goode , Michael S Hofman , Shahneen Sandhu

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Genitourinary Cancer—Prostate, Testicular, and Penile

Track

Genitourinary Cancer—Prostate, Testicular, and Penile

Sub Track

Prostate Cancer– Advanced/Castrate-Resistant

Clinical Trial Registration Number

NCT03874884

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr 5064)

DOI

10.1200/JCO.2023.41.16_suppl.5064

Abstract #

5064

Poster Bd #

158

Abstract Disclosures

Similar Posters

First Author: Daniel Khalaf

First Author: Justine Panian

First Author: Anis Hamid

First Author: Santosh Gupta